| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787570 | Journal of Thoracic Oncology | 2018 | 25 Pages |
Abstract
AC0010 had a well-tolerated safety profile and promising antitumor activity in patients with NSCLC with acquired resistance to a first-generation EGFR TKI, supporting its continued development.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yuxiang MD, Xin PhD, Hongyun MD, Wenfeng MD, Yang MD, Jieying MD, Lu MD, Weicong PhD, Ji PhD, Shaokun PhD, Zhou PhD, Wanhong PhD, Xiao PhD, Pei PhD, Li MD,